Photo of: Minister Cockrill along with representatives from the Saskatchewan Cancer Agency, Ovarian Cancer Canada and Ovarian cancer survivors.

Photo by: Danielle Dufour

 

Health Minister Jeremy Cockrill announced the province will provide coverage for two new breakthrough treatment options for women with advanced Ovarian cancer beginning December 1st.

Ovarian cancer is one of the deadliest forms of cancer for women in Canada.

“(In Canada) There’s about 3100 people that will be diagnosed with Ovarian cancer this year, and of those 56 per cent will not survive five years,” said Stephanie Gosselin, Director of Community Impact and Advocacy with Ovarian Cancer Canada.

Gosselin pointed out the standard treatment options haven’t changed in decades and would typically include a variation of surgery, followed by some kind of chemotherapy or chemotherapy followed by surgery.

Ovarian Cancer Canada initially launched a national campaign in May of this year to advocate for these new treatments that were being used in the United States, the United Kingdom and other parts of the world. Gosselin said, “So exciting to be here today to be the first province to actually announce a listing of the drugs.”

Although Gosselin stated these drugs are not a cure for Ovarian cancer, they have the potential to extend life for those impacted.

“Ovarian cancer remains one of the most challenging cancers we treat,” said Darryl Boehm, Director of Oncology Pharmacy Services at the Saskatchewan Cancer Agency. “Many patients initially respond to treatment, but unfortunately the disease often returns.”

There is no early detection or early screening test for Ovarian cancer. This often results in patients being diagnosed in late stages of cancer, typically people in their early 60’s but can impact women of all ages.

A common misconception is that a Pap smear test, or cervical screening tests for Ovarian cancer. It does not.

Photo by: Danielle Dufour

“Now, when facing a cancer diagnosis, a patient’s access to effective treatment can make significant difference in their healthcare journey,” said Minister Cockrill.

Coverage for Elahere and Keytruda will be available for eligible patients who meet certain criteria, whose disease has stopped responding to traditional treatments such as chemotherapy.

“We’ll be following the recommendations from Canada’s Drug Agency for the reimbursement eligibility criteria, which is patients would have to have at least one prior systemic therapy regimen, and they have to be resistant to platinum chemotherapy…with Elahere there’s a specific marker on the cells, so they have to test positive for this marker, and with Keytruda there’s another marker, so there’s a test that will determine eligibility.”

These innovative treatment options can help delay disease progression, and in some cases, help patients live longer while maintaining or improving quality of life.

Saskatchewan will be one of the first provinces in Canada to offer funding for these treatments through the provincial drug plan.

“We expect this investment to probably be in the neighborhood of half a million dollars a year for these two treatments,” said Minister Cockrill.

Approximately eight to 10 Saskatchewan patients each year are expected to benefit from access to these new treatment options.

“These investments are really about helping people live longer and live a higher quality of life,” said Minister Cockrill.

Photo by: Danielle Dufour

Brenda Tunstead, who has stage 4 Ovarian cancer, was at the Legislative Building when the announcement was made.

“It’s very exciting news because I possibly could be eligible for one of the drugs,” said Tunstead. “I’ve had many reoccurrences already.”

Tunstead is still receiving chemotherapy treatment but is not sure how long the treatment will help her, and she is anxious to talk to her doctor to see if she will be eligible for one of these new treatment options.

“The most important thing is it will give me time with my family, that’s why we’re all here, we want to continue to live, we want to fight,” said Tunstead.

The Saskatchewan government says over $300 million will be invested between 2026 to 2027 in the Saskatchewan Cancer Agency to support prevention, early detection, diagnosis and treatment support services.